Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular

Summary

The aim of this study is to evaluate whether the use of Sugammadex for reversing the neuromuscular blocking effects of rocuronium during neurointerventional procedures can speed recovery of neuromuscular function. Half of participates will receive Neostigmine with glycopyrrolate, while the other half will receive Sugammadex.

Timeline

Start

2017-11-14

Primary completion

2020-12-31

Completion

2021-02-01

Outcome

Mixed primary results

registry PRIMARY OUTCOME 2: TOF Ratio at 90 Min [time frame: at 90 minutes after the administration of the reversal agent] NCT03322657 ↗

registry analysis (superiority test); Neostigmine With Glycopyrrolate vs Sugammadex; p = 0.13; Median Difference (Final Values) 6.3 (95% CI -2.0 to 14) NCT03322657 ↗

Publications

• Farag E, Rivas E, Bravo M, Hussain S, Argalious M, Khanna S, Seif J, Pu X, Mao G, Bain M, Elgabaly M, Esa WAS, Sessler DI. Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular Block in Patients Having Catheter-Based Neurointerventional Procedures: A Randomized Trial. Anesth Analg. 2021 Jun 1;132(6):1666-1676. doi: 10.1213/ANE.0000000000005533.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Neostigmine	Other / unclassified	0.07 mg/kg	—
Subject	Sugammadex	Other / unclassified	4 mg/kg	—
Comparator	Glycopyrrolate	Small molecule	0.01 mg/kg	—

Indications

No indication recorded.